1
/
of
1
Ateron (Abiraterone Acetate)
Ateron (Abiraterone Acetate)
Regular price
₱72,000.00 PHP
Regular price
Sale price
₱72,000.00 PHP
Unit price
₱600.00 each
Taxes included.
Quantity
Couldn't load pickup availability
Ateron (Abiraterone Acetate) is a prescription oral medication designed for the treatment of advanced prostate cancer. As an androgen biosynthesis inhibitor, abiraterone acetate works by blocking CYP17, a crucial enzyme in the testosterone production pathway. By reducing circulating androgen levels, this medication helps slow the progression of hormone-dependent prostate cancer cells.
Ateron is primarily indicated for metastatic castration-resistant prostate cancer (mCRPC), a condition where cancer continues to progress despite surgical or chemical castration. It is also used in combination with prednisone for advanced prostate cancer management in patients who require hormonal therapy. The dual mechanism of enzyme inhibition makes abiraterone acetate an essential option in oncology treatment protocols for men with advanced disease stages.
Clinical use of abiraterone acetate requires careful patient selection and ongoing medical supervision. The medication is contraindicated in patients with documented hypersensitivity to abiraterone acetate or any formulation component, as well as in individuals with severe hepatic impairment classified as Child-Pugh Class C. These contraindications reflect the drug's hepatic metabolism and potential for serious adverse reactions in susceptible populations.
Dosing of Ateron must be individualized based on patient factors, disease stage, and concurrent medications as determined by your oncologist or treating physician. Prednisone coadministration is typically required to mitigate mineralocorticoid excess effects associated with CYP11A1 inhibition. This medication requires strict adherence to medical guidance and should never be initiated or adjusted without direct consultation with a qualified healthcare provider familiar with prostate cancer management.
Ateron is primarily indicated for metastatic castration-resistant prostate cancer (mCRPC), a condition where cancer continues to progress despite surgical or chemical castration. It is also used in combination with prednisone for advanced prostate cancer management in patients who require hormonal therapy. The dual mechanism of enzyme inhibition makes abiraterone acetate an essential option in oncology treatment protocols for men with advanced disease stages.
Clinical use of abiraterone acetate requires careful patient selection and ongoing medical supervision. The medication is contraindicated in patients with documented hypersensitivity to abiraterone acetate or any formulation component, as well as in individuals with severe hepatic impairment classified as Child-Pugh Class C. These contraindications reflect the drug's hepatic metabolism and potential for serious adverse reactions in susceptible populations.
Dosing of Ateron must be individualized based on patient factors, disease stage, and concurrent medications as determined by your oncologist or treating physician. Prednisone coadministration is typically required to mitigate mineralocorticoid excess effects associated with CYP11A1 inhibition. This medication requires strict adherence to medical guidance and should never be initiated or adjusted without direct consultation with a qualified healthcare provider familiar with prostate cancer management.
Share
